newsfilter
← Latest News
GlobeNewswire·

Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Initiated higher-dose CBeyond Expansion Study (Part C) to generate higher-exposure human safety and pharmacokinetic data with 400 mg and 600 mg IV cohorts;Received written FDA Type C meeting minutes; feedback is